Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial

BACKGROUND: Obesity is a risk factor for breast cancer (BC) development, recurrence, and death. In view of this, we aimed to investigate the clinical value of obesity in BC patients treated with anti-HER2 therapies in the NeoALTTO trial, which randomized 455 patients to neo-adjuvant lapatinib, trast...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Cosimo, Serena, Porcu, Luca, Agbor-tarh, Dominique, Cinieri, Saverio, Franzoi, Maria Alice, De Santis, Maria Carmen, Saura, Cristina, Huober, Jens, Fumagalli, Debora, Izquierdo, Miguel, Piccart, Martine, Daidone, Maria Grazia, de Azambuja, Evandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590445/
https://www.ncbi.nlm.nih.gov/pubmed/33109233
http://dx.doi.org/10.1186/s13058-020-01356-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590445/
https://www.ncbi.nlm.nih.gov/pubmed/33109233
http://dx.doi.org/10.1186/s13058-020-01356-w

Ejemplares similares